Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea

Published 27/09/2022, 15:21
Updated 27/09/2022, 16:10
© REUTERS Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea

  • Ocular Therapeutix Inc (NASDAQ: OCUL) announced interim 7-month data from its U.S. Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration (wet AMD) and other retinal diseases.
  • Interim data showed that the single OTX-TKI implant was generally well tolerated with a favorable safety profile. No drug-related ocular or systemic serious adverse events (SAEs) were observed.
  • After the mandated aflibercept injection, one SAE of endophthalmitis was observed in the OTK-TKI arm.
  • Single OTX-TKI implant demonstrated stable and sustained best corrected visual acuity (BCVA) and central subfield thickness (CSFT), comparable with Regeneron Pharmaceuticals Inc's (NASDAQ: NASDAQ:REGN) Eylea (aflibercept).
  • About 80% of subjects in the OTX-TKI arm were rescue-free for up to 6 months, and 73% of subjects in the OTX-TKI arm were rescue-free for up to 7 months. FDA has not reviewed these data.
  • The company plans to complete its analysis, meet with the FDA to discuss potential future clinical trial requirements, and initiate a Phase 2 wet AMD trial in Q3 of 2023.
  • Ocular also plans to follow subjects in the Phase 1 trial at least until their respective one-year anniversaries of initial dosing under the clinical trial protocol.
  • It also plans to initiate a U.S.-based Phase 1 clinical trial to evaluate OTX-TKI for diabetic retinopathy in Q1 of 2023.
  • Price Action: OCUL shares are down 7% at $4.91 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.